Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study

the Australian and New Zealand Inflammatory Bowel Disease Consortium, J. D. Doecke, F. Hartnell, P. Bampton, S. Bell, G. Mahy, Z. Grover, P. Lewindon, L. V. Jones, K. Sewell, K. Krishnaprasad, R. Prosser, D. Marr, J. Fischer, G. R Thomas, J. V. Tehan, N. S. Ding, S. E. Cooke, K. Moss, A. SechiP. De Cruz, R. Grafton, S. J. Connor, I. C. Lawrance, R. B. Gearry, J. M. Andrews, G. L. Radford-Smith

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study'. Together they form a unique fingerprint.

Medicine & Life Sciences